AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (1.5 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Viewpoint | Open Access

Galectins dysregulation: A way for cancer cells to invade and pervade

MAHMOUD M. ABDELFATTAH1, REHAM HELWA1,2( )
Molecular Cancer Biology Group, Zoology Department, Faculty of Science, Ain Shams University, Cairo, Egypt
Faculty of Basic Science, King Salman International University, South Sinai, Egypt
Show Author Information

Abstract

Galectins are sticky molecules that bind to β-galactoside. Their interactions render them essential players in many cellular processes. The imbalance of galectin expression was reported in many diseases. In cancer, galectins interact with the extracellular matrix, evade the immune system, and potentially have broad interactions with blood components. In the last ten years, since 2010, we did focus on galectin research in different cancer types. Our findings showed an interaction between cancer cells and erythrocytes via galectin-4. Moreover, we found that upregulation of galectins was associated with lymph node metastasis in ovarian cancers. Hence, with this, we shortly review some important aspects of galectins and their potential importance in more profound understanding of cancer progression and the field of cancer biomarkers.

References

【1】
【1】
 
 
Oncology Research
Pages 129-135

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
ABDELFATTAH MM, HELWA R. Galectins dysregulation: A way for cancer cells to invade and pervade. Oncology Research, 2022, 30(3): 129-135. https://doi.org/10.32604/or.2022.026838

788

Views

33

Downloads

7

Crossref

7

Web of Science

6

Scopus

Received: 28 September 2022
Accepted: 13 December 2022
Published: 12 January 2023
© The Author 2024.

This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.